That s what I think about your ideas

Etoricoxib, instructions for use (Method and dosage)

The medicine is intended for oral administration. Dosage and treatment regimen depends on the disease and doctor's recommendations.

Usually take from 0.06 to 0.12 g once a day. click for example With liver failure, it is not recommended to take more than 60 mg of the drug per day..

Use of the substance Etoricoxib

Symptomatic therapy of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis.

Hypersensitivity; a combination of bronchial asthma, recurrent polyposis of the nose or paranasal sinuses and intolerance to acetylsalicylic acid and other NSAIDs (including a history); erosive and ulcerative lesions of the mucous membrane of the stomach or duodenum, active bleeding in the digestive tract, cerebrovascular or other bleeding; inflammatory bowel disease (Crohn's disease, ulcerative colitis) in the acute phase; bleeding disorder, including hemophilia; chronic heart failure (NYHA grades II – IV), severe liver failure (more than 9 points on the Child-Pugh scale) or active liver disease, severe chronic renal failure (creatinine Cl 140/90 mm Hg in uncontrolled arterial hypertension, pregnancy, lactation, age up to 16 years.

A history of gastrointestinal ulceration, the presence of Helicobacter pylori infection, prolonged use of NSAIDs, frequent alcohol consumption, severe physical illness, dyslipidemia / hyperlipidemia, diabetes mellitus, hypertension, edema and fluid retention, smoking, impaired renal function (Cl creatinine Dosage and administration

Inside, once a day. The minimum effective dose should be used as short as possible. Recommended doses are 60–120 mg / day. In patients with liver failure (5–9 points on the Child-Pugh scale), it is recommended not to exceed a daily dose of 60 mg.

In 2005, FDA recommendations 1 were adopted, stating that all NSAIDs should have an annotation in their annotations indicating the risk of cardiovascular events and gastrointestinal bleeding (special warning - Black box warning for NSAIDs). NSAIDs may increase the risk of serious cardiovascular events. thrombotic complications, including myocardial infarction and stroke, with a possible fatal outcome. All NSAIDs, both selective COX-2 inhibitors and non-selective, may have a similar risk. This risk may increase with prolonged treatment..

NSAIDs increase the risk of serious side effects from the gastrointestinal tract, including bleeding, ulceration, and perforation of the stomach or intestines. These complications can occur at any time during the use of NSAIDs without warning signs; a fatal outcome is possible. Older patients have a higher risk of serious gastrointestinal complications, the likelihood of these complications also increases with prolonged use. During the first 2 weeks of taking the drug and periodically in the future, careful monitoring of blood pressure is required. It is necessary to regularly monitor indicators of liver and kidney function; in case of an increase in the activity of hepatic transaminases by more than 3 times, etoricoxib must be canceled. The need to continue taking the drug and the possibility of reducing its dose should be periodically assessed. Do not use simultaneously with other NSAIDs. It is not recommended to use while drivers of vehicles and people whose profession is associated with increased concentration of attention..

Structure

One tablet contains

active substance - etoricoxib 90 mg

excipients: calcium hydrogen phosphate anhydrous, microcrystalline cellulose, croscarmellose sodium, magnesium stearate,

film coating composition:

 

  • Opadray® II Green 39K11520 (lactose monohydrate - 35%, hypromellose - 33%, titanium dioxide E171 - 16.6%, triacetin - 8.0%, indigo carmine varnish E132 - 5.4%, iron (III) yellow oxide E172 - 1.9%), carnauba wax (for 60 mg);
  • Opadray® II White 39K18305 (lactose monohydrate - 35%, hypromellose - 33%, titanium dioxide E171 - 24.0%, triacetin - 8.0%), carnauba wax (for 90 mg);
  • Opadray® II Green 39K11529 (lactose monohydrate - 35%, hypromellose - 33%, titanium dioxide E171 - 21.6%, triacetin - 8.0%, indigo carmine varnish E132 - 1.6%, iron (III) yellow oxide E172 - 0.9%), carnauba wax (for 120 mg).

 

Distribution

Etoricoxib binds to human plasma proteins by 92% with a concentration range from 0.05 to 5 μg / ml. http://en.m.wikipedia.org/wiki/Etoricoxib In humans, the volume of distribution in equilibrium (Vdss) is about 120 l.

Etoricoxib crosses the placental barrier in rats and rabbits, as well as through the blood-brain barrier in rats.